PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS
Publication
, Journal Article
Desjardins, A; Reardon, DA; Peters, KB; Herndon, JE; Gururangan, S; Norfleet, J; Friedman, HS; Vredenburgh, JJ
Published in: NEURO-ONCOLOGY
November 1, 2011
Duke Scholars
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
November 1, 2011
Volume
13
Start / End Page
90 / 90
Publisher
OXFORD UNIV PRESS INC
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Reardon, D. A., Peters, K. B., Herndon, J. E., Gururangan, S., Norfleet, J., … Vredenburgh, J. J. (2011). PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS. NEURO-ONCOLOGY, 13, 90–90.
Desjardins, Annick, David A. Reardon, Katherine B. Peters, James E. Herndon, Sridharan Gururangan, Julie Norfleet, Henry S. Friedman, and James J. Vredenburgh. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” NEURO-ONCOLOGY 13 (November 1, 2011): 90–90.
Desjardins A, Reardon DA, Peters KB, Herndon JE, Gururangan S, Norfleet J, et al. PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS. NEURO-ONCOLOGY. 2011 Nov 1;13:90–90.
Desjardins, Annick, et al. “PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.” NEURO-ONCOLOGY, vol. 13, OXFORD UNIV PRESS INC, Nov. 2011, pp. 90–90.
Desjardins A, Reardon DA, Peters KB, Herndon JE, Gururangan S, Norfleet J, Friedman HS, Vredenburgh JJ. PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS. NEURO-ONCOLOGY. OXFORD UNIV PRESS INC; 2011 Nov 1;13:90–90.
Published In
NEURO-ONCOLOGY
ISSN
1522-8517
Publication Date
November 1, 2011
Volume
13
Start / End Page
90 / 90
Publisher
OXFORD UNIV PRESS INC
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences